HBP — Helix Biopharma Share News
0.000.00%
Last trade - 00:00- CA$75.61m
- CA$73.13m
Brief: Helix Biopharma Reports Q3 Shr Loss C$0.02
Brief: Helix Biopharma Corp Reports Q3 Loss Per Share C$0.03
Brief: Helix BioPharma Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47
Brief: Helix Biopharma Corp. Announces Regulatory Approval To Dose Patients In A Phase II Randomized Study of L-DOS47 With Vinorelbine And Cisplatin
Brief: Helix Biopharma Welcomes Daniel Von Hoff, Kazimierz Roszkowski-Sliz And Robert Gillies To Its Scientific And Strategic Advisory Board
Develop Car-T For Hematological Malignancies
Brief: Helix Biopharma Reports Q2 Loss Per Share of C$0.03
Brief: Helix Biopharma To Explore Partnership, Joint Development Or Licensing Of Drug
Brief: Helix Biopharma Signs Binding Letter Of Intent For Development Of New Car-T Technologies
Brief: Helix Biopharma Q1 Loss Per Share C$0.02
Brief: Helix BioPharma Corp Announces Management Change
Brief: Helix Biopharma announces FDA approval to accelerate dose escalation for U.S. Phase I clinical study
Brief: Helix Biopharma initiates enrollment in the third dosing cohort of its lung cancer drug l-DOS47
Brief: Helix Biopharma and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade
Brief: Helix BioPharma Corp director resigns
Brief: Helix Biopharma Q3 loss per share $0.03
Brief: Helix Biopharma Q2 loss per share C$0.03
Brief: Helix Biopharma says Heman Chao to become CEO
Brief: Helix Biopharma Corp announces licence for worldwide right to anti-CEACAM6 antibody from Government of Canada